Toll-Like Receptor 4 and Matrix Metalloproteases 11 and 13 as Predictors of Tumor Recurrence and Survival in Stage II Colorectal Cancer.
Noemi EiroJuan Francisco CarriónSandra CidAlejandro AndicoecheaJosé Luis García-MuñizLuis O GonzálezFrancisco J VizosoPublished in: Pathology oncology research : POR (2019)
Current clinical-pathologic stratification factors do not allow clear identification of high-risk stage II colorectal cancer (CRC) patients. Therefore, the identification of additional prognostic markers is desirable. Toll-like receptor (TLR)-4 is activated during tumorigenesis and matrix metalloproteases (MMPs) are involved in invasion and metastasis. We aimed to evaluate the expression and clinical relevance of TLR4, MMP11 and MMP13 for patients with stage II CRC. Immunohistochemistry was used to study the expression of TLR4, MMP11 and MMP13 in 96 patients with stage II CRC. We measured the global expression and the expression by different cell types (tumor cells, cancer-associated fibroblasts (CAFs) and mononuclear inflammatory cells (MICs)). The potential relationship between expressions of factors and different prognostic variables were evaluated. Our results show significant relationships between either TLR4 expression by tumor cells and MMP11 expression by CAFs and high risk of tumor recurrence. In addition, the concurrence of age ≥ 75 years and the non-expression of MMP11 by CAFs identify a subgroup of patients with a good prognosis. Our results show that TLR4 expression by tumor cells and MMP11 expression by CAFs may to improve the identification of patients with stage II CRC with a high-risk of relapse.
Keyphrases
- toll like receptor
- poor prognosis
- inflammatory response
- immune response
- nuclear factor
- randomized controlled trial
- squamous cell carcinoma
- stem cells
- cell proliferation
- clinical trial
- signaling pathway
- oxidative stress
- bone marrow
- induced apoptosis
- climate change
- cell therapy
- open label
- chronic kidney disease
- neoadjuvant chemotherapy
- rectal cancer
- extracellular matrix